Thursday, 2 July 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 02 July 2026
News

Media frenzy bites AstraZeneca

Posted 2 July 2026 AM

The backlash to AstraZeneca's decision to remove the monthly 3.6mg dose of GnRH agonist Zoladex from the PBS is not blowing over, despite assurances from the pharma that it will continue supply for those women who need it.

On Tuesday 7News ran an "exclusive" segment on the withdrawal, emphasising AstraZeneca is "a multi-billion dollar pharmaceutical company" and highlighting the experience of breast cancer survivor Rhiannon Abshoff, diagnosed at 32 when her son was just a year old.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (25)

Access & Reimbursement (2)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (6)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.